Raymond James reiterates Strong Buy on Globe Life stock, $208 target
Raymond James reiterated a Strong Buy rating and $208 price target for Globe Life (GL) after meetings with its leadership. The company expects excess cash flows of $850-950M in 2027, up from $600-700M in 2026, and has an 11% free cash flow yield. GL reported Q3 2026 net operating income of $4.84 per diluted share, missing estimates, but revenue rose to $1.6B, beating forecasts. Analysts have mixed reviews, with some lowering targets due to medical claims concerns.
How this was made
The 30-second read
Why it matters
The reiteration of a Strong Buy and a higher price target could provide short‑term upside, but mixed analyst opinions and claim‑cost pressures temper the rally potential.
Market read
Analyst rating update for GL may spark modest buying interest, but broader market impact is limited.
What to watch
Recent analyst downgrades and lower price targets from other banks suggest mixed sentiment.
Background
Globe Life recently reported Q3 2026 results that missed EPS estimates but beat revenue forecasts. Analysts have adjusted their targets amid concerns about health‑claims volatility.
Ticker impact
Raymond James reiterated a Strong Buy rating and raised the price target to $208 for Globe Life (GL) after meeting with company leadership.
potential upward pressure as the market prices in the higher target
The rating upgrade and $208 target are new analyst actions that could attract buying, but the stock already trades near recent highs and the upgrade is a reiteration rather than a fresh surprise.
Market effects
Minimal impact on the insurance sector; the rating change is company‑specific.
Limited to U.S. investors focused on GL.
Low
Counterpoint
The upgrade may be premature given lingering concerns over medical‑claims volatility.
Key entities
- CompanyGlobe Life
U.S. insurer (ticker GL) subject of the analyst rating upgrade.
- Research FirmRaymond James
Issued the Strong Buy rating and $208 price target.
